{"version":"1.0","type":"link","title":"Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.","author_name":"Lei L 외","author_url":"https://prs-insight.online/author/Lei%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/88823","thumbnail_width":1200,"thumbnail_height":630}